Arcutis Biotherapeutics
ARQT
ARQT
185 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
185
Holders Change
+18
Holders Change %
+10.78%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
$91.3M |
| 2 |
SCM
Suvretta Capital Management
New York
|
$93M |
| 3 |
BlackRock
New York
|
$80.2M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
$12.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
$27.3M |
